Pfizer has signed a deal worth up to $2.6bn with China’s Starna Therapeutics, adding three experimental cell therapies for autoimmune diseases to its pipeline.
The agreement gives the US drugmaker exclusive rights to develop, manufacture and sell CAR-T therapy treatments outside Greater China, with an option to expand those rights to Greater China in the future.
Starna will receive $330m upfront and could earn a further $2.3bn if the programmes meet development and commercial milestones. The biotech is also eligible for royalties on sales of any products that reach the market. All three programmes are still at an early stage, ahead of applications to begin human trials.
Bringing CAR-T to autoimmune disease
CAR-T therapy uses immune cells that have been modified to recognise and attack specific targets. In autoimmune disease, the aim is to eliminate immune cells that contribute to the condition.
Conventional CAR-T treatment involves collecting a patient’s cells, modifying them in a laboratory and returning them to the patient.
Starna’s approach, however, known as in vivo CAR-T, is designed to do the reprogramming inside the body, removing the need to collect and modify cells for each patient.
For the three programmes in the deal, how safely and effectively that process works in people remains to be established. Pfizer will lead clinical development outside Greater China and plans to use its US facilities to manufacture supplies for the first trials.
Michael Vincent, M.D., Ph.D., Chief Inflammation & Immunology Officer, Pfizer said: “In vivo CAR-T is an emerging and promising approach for treating autoimmune diseases, and the patients who might benefit most are those for whom today’s options fall short.
“Pfizer has significant experience in developing and manufacturing RNA-based medicines globally, and Starna’s in vivo CAR-T programs and technology give us a powerful way to pursue these approaches.”
Bringing ‘transformative therapies’ to patients
The agreement also will also give Pfizer access to Starna’s technology for research in other diseases like inflammation, immunology and cancer.
The deal also gives Pfizer the option to secure exclusive rights to new drug candidates that emerge from its research with Starna, allowing it to build on the initial three programmes as the research progresses.
Rongkuan Hu, Ph.D., Chief Executive Officer, Starna Therapeutics, said about the deal: “Our vision at Starna is to unlock the potential of RNA medicines to transform patient care. We believe our proprietary targeted LNP delivery platform and RNA technology provide a strong foundation for advancing in vivo CAR-T therapies.
“We are excited to join forces with Pfizer, a global leader in drug development, to bring transformative therapies to patients worldwide,” he added.
The Starna agreement is the latest in a string of deals with Chinese based biopharmaceuticals for Pfizer, and follows a previous deal worth up to $10.5bn with Innovent Biologics in May and an earlier agreement with 3SBio in 2025.
It comes as Pfizer looks for new sources of growth amid falling sales of its COVID-19 products and looming patent expiries and extends it’s work with Chinese biotechs into autoimmune cell therapy.